Navigation Links
Vaccine Partnering Terms and Agreements
Date:6/13/2012

NEW YORK, June 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Partnering Terms and Agreements
http://www.reportlinker.com/p0655260/Vaccine-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication


Summary
The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in vaccine and adjuvant partnering deals
Deal terms analysis
Partnering agreement structure
Partnering contract documents
Top deals by value
Most active dealmakers
Average deal terms for vaccines
Description
The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Vaccine Partnering Terms and Agreements includes:

Trends in vaccine dealmaking in the biopharma industry since 2007
Analysis of vaccine deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life vaccine deals
Access to over 1,500 vaccine deal documents
The leading vaccine deals by value since 2007
Most active vaccine dealmakers since 2007
The leading vaccine partnering resources
In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise vaccine rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Benefits
Vaccine Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of vaccine and adjuvant deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of vaccine agreements with numerous real life case studies
Comprehensive access to over 1500 actual vaccine contracts entered into by the world's biopharma companies
Detailed access to actual vaccine contracts enter into by the leading fifty bigpharma companies
Insight into the terms included in a vaccine agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in vaccine dealmaking

2.1. Introduction
2.2. Companion vaccine over the years
2.3. Bigpharma vaccine dealmaking activity
2.4. Bigpharma not active in vaccines
2.5. Vaccine partnering by deal type
2.6. Vaccine partnering by disease type
2.7 Average deal terms for vaccine
2.7.1 Vaccine headline values
2.7.2 Vaccine upfront payments
2.7.3 Vaccine milestone payments
2.7.4 Vaccine royalty rates

Chapter 3 – Leading vaccine deals

3.1. Introduction
3.2. Top vaccine deals by value
3.3. Top vaccine deals involving bigpharma

Chapter 4 – Bigpharma vaccine deals

4.1. Introduction
4.2. How to use bigpharma vaccine partnering deals
4.3. Bigpharma vaccine partnering company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Takeda
Teva
UCB
Valeant
Warner Chilcott
Watson

Chapter 5 – Vaccine dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
5.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
5.5. By therapy area
Anesthetics
Cardiovascular
Central nervous system
Dental
Dermatology
Gastrointestinal
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Psychiatry
Public health
Respiratory
Sexual health
5.6. By associated technology type
Adjuvant

Chapter 6 – Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
Appendices

Appendix 1 – Deal type definitions
Appendix 2 – Example vaccine partnering agreement
About Wildwood Ventures
Figures in report

Figure 1: Vaccine partnering since 2007
Figure 2: Bigpharma – top 50 – vaccine deals 2007 to 2012
Figure 3: Bigpharma vaccine deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in vaccine partnering 2007-2012
Figure 5: Vaccine partnering by deal type since 2007
Figure 6: Vaccine partnering by disease type since 2007
Figure 7: Vaccine partnering by infectives target since 2007
Figure 8: Vaccine partnering by oncology target since 2007
Figure 9: Vaccine deals with a headline value – by stage of development
Figure 10: Vaccine deal headline value distribution, US$million – discovery stage
Figure 11: Vaccine deal headline value distribution, US$million – preclinic stage
Figure 12: Vaccine deal headline value distribution, US$million – phase I stage
Figure 13: Vaccine deal headline value distribution, US$million – phase II stage
Figure 14: Vaccine deal headline value distribution, US$million – phase III stage
Figure 15: Vaccine deal headline value distribution, US$million – marketed stage
Figure 16: Vaccine deal headline value – median value by stage of development
Figure 17: Vaccine deals with upfront payment values – by stage of development
Figure 18: Vaccine deal upfront payment distribution, US$million – discovery stage deals
Figure 19: Vaccine deal upfront payment distribution, US$million – prelinic stage deals
Figure 20: Vaccine deal upfront payment distribution, US$million – phase I stage deals
Figure 21: Vaccine deal upfront payment distribution, US$million – phase II stage deals
Figure 22: Vaccine deal upfront payment distribution, US$million – phase III stage deals
Figure 23: Vaccine deal upfront payment distribution, US$million – marketed stage deals
Figure 24: Vaccine deal upfront value – median value by stage of development
Figure 25: Vaccine deals with milestone payment – by stage of development
Figure 26: Vaccine deal milestone payment distribution, US$million – discovery stage deals
Figure 27: Vaccine deal milestone payment distribution, US$million – prelinic stage deals
Figure 28: Vaccine deal milestone payment distribution, US$million – phase I stage deals
Figure 29: Vaccine deal milestone payment distribution, US$million – phase II stage deals
Figure 30: Vaccine deal milestone payment distribution, US$million – phase III stage deals
Figure 31: Vaccine deal milestone payment distribution, US$million – marketed stage deals
Figure 32: Vaccine deal milestone payments – median value by stage of development
Figure 33: Vaccine deals with royalty rates
Figure 34: Top vaccine deals by value since 2007
Figure 35: Top vaccine deals signed by bigpharma value since 2007
Figure 36: Recent deals (Jan 2007 to May 2012) - By therapy area (Anesthetics
Figure 37: Recent deals (Jan 2007 to May 2012) - By therapy area (Cardiovascular
Figure 38: Recent deals (Jan 2007 to May 2012) - By therapy area (Central Nervous System)
Figure 39: Recent deals (Jan 2007 to May 2012) - By therapy area (Dental)
Figure 40: Recent deals (Jan 2007 to May 2012) - By therapy area (Dermatology)
Figure 41: Recent deals (Jan 2007 to May 2012) - By therapy area (Gastrointestinal)
Figure 42: Recent deals (Jan 2007 to May 2012) - By therapy area (Genitourinary)
Figure 43: Recent deals (Jan 2007 to May 2012) - By therapy area (Hematology)
Figure 44: Recent deals (Jan 2007 to May 2012) - By therapy area (Hospital care)
Figure 45: Recent deals (Jan 2007 to May 2012) - By therapy area (Immunology)
Figure 46: Recent deals (Jan 2007 to May 2012) - By therapy area (Infectives)
Figure 47: Recent deals (Jan 2007 to May 2012) - By therapy area (Inflammatory)
Figure 48: Recent deals (Jan 2007 to May 2012) - By therapy area (Metabolic)
Figure 49: Recent deals (Jan 2007 to May 2012) - By therapy area (Musculoskeletal)
Figure 50: Recent deals (Jan 2007 to May 2012) - By therapy area (Oncology)
Figure 51: Recent deals (Jan 2007 to May 2012) - By therapy area (Ophthalmics)
Figure 52: Recent deals (Jan 2007 to May 2012) - By therapy area (Psychiatry)
Figure 53: Recent deals (Jan 2007 to May 2012) - By therapy area (Public health)
Figure 54: Recent deals (Jan 2007 to May 2012) - By therapy area (Respiratory)
Figure 55: Recent deals (Jan 2007 to May 2012) - By therapy area (Sexual health)
Figure 56: Online partnering resources
Figure 57: Forthcoming partnering events
Figure 58: Deal type definitions
Figure 59: Vaccine partnering agreement between Novavax and LG Life Sciences, March 2011


To order this report:
: Vaccine Partnering Terms and Agreements

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 



 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
2. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
3. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
4. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
5. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
6. Global Human Vaccines Industry
7. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
8. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
9. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
10. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
(Date:6/24/2016)... ... 24, 2016 , ... To succeed under value-based payments, healthcare ... unsure how to move forward, given the need to sustain current operations. PYA ... to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers ...
Breaking Medicine News(10 mins):